Basic and Clinical Study of Cardiac Ganglion Catheter Ablation for the Treatment of Significant Bradycardia

NCT07468383 · tracked via the Priya Life Science China tracker

Sponsor

Beijing Anzhen Hospital

Phase

Not applicable

Started

2025-08-01

Last updated

2026-03-13

Condition(s) studied

Symptomatic BradycardiaAutonomic Nervous System Diseases

Investigational drug(s) / intervention(s)

CardioneuroablationSham Control

Cardioneuroablation: The procedure is performed under local anesthesia with conventional sedation using 1-3 mg of midazolam. The decision to administer additional sedation is assessed based on the patient's level of consciousness. The femoral vein is punctured, and a sheath is placed. Through this femoral venous sheath, catheters are advanced via the right atrium to position electrodes in the coronary sinus and the right ventricle. Under the guidance of intracardiac echocardiography and fluoroscopy (X-ray), a transseptal puncture is performed. The ablation catheter is then introduced into the left atrium through the transseptal sheath to sequentially perform catheter ablation of the left atrial and, selectively, the right atrial ganglionated plexi.

Sham Control: Throughout the procedure, the patient continuously wears over-ear headphones playing music and an eye mask. The surgery is performed under local anesthesia with conventional sedation using 1-3 mg of midazolam. The decision to administer additional sedation is assessed based on the patient's level of consciousness. Preoperative preparation, femoral vein puncture, placement of electrode catheters, and the electrophysiological study protocol are the same as in the intervention group; however, no transseptal puncture, ganglion mapping, or catheter ablation is performed.

Study summary

This study adopts a strategy combining basic research with clinical investigation to systematically explore the therapeutic value of cardioneuroablation in the treatment of vagally-mediated bradycardia. The study design fully considers the complexity of the scientific question and the feasibility of clinical translation. Through rigorous experimental design and standardized operational procedures, the reliability and reproducibility of the study results are ensured.

Eligibility

Sex

ALL

Min age

18 Years

Max age

65 Years

Healthy volunteers

Inclusion Criteria: 1. Age range: 18 - 65 years old 2. Have symptoms related to bradycardia (syncope, dizziness, blackout, palpitations, fatigue, listlessness, inability to concentrate and decreased activity endurance, etc.) 3. Meet one of the following conditions: ①Dynamic electrocardiogram shows an average heart rate of less than 50 beats per minute or there is a heart arrest lasting more than 3 seconds during the day; ②Transient second or third degree atrioventricular conduction block without hemodynamic disorders during the day 4. The atropine test showed that the sinus heart rate increased by ≥ 25%, or the heart rate was ≥ 90 beats per minute, or the atrioventricular conduction block was significantly improved to be no more than first-degree atrioventricular conduction block. Exclusion Criteria: 1. A history of severe trauma caused by bradycardia 2. Regular use of antiarrhythmic drugs within the past 3 months 3. Prior implantation of a cardiac pacemaker 4. Existing implantation of, or indication for implantation of, electronic devices with pacing function, such as cardiac contractility modulators (CCMs), implantable cardioverter-defibrillators (ICDs), or cardiac resynchronization therapy (CRT) devices 5. Bradycardia or atrioventricular block caused by medications or other reversible factors (e.g., hyperkalemia, hypothyroidism) 6. Bradycardia or atrioventricular block associated with obstructive sleep apnea syndrome (OSAS) 7. Coronary revascularization within the past 3 months, or unstable coronary heart disease despite standardized medical treatment or revascularization 8. Stroke or transient ischemic attack (TIA) within the past 3 months 9. A history of open-heart surgery 10. Severe congenital heart disease 11. Complicated with severe ventricular arrhythmia 12. Severe cardiac insufficiency with left ventricular ejection fraction (LVEF) ≤ 35% 13. Severe cardiomyopathy, such as hypertrophic obstructive cardiomyopathy (HOCM), dilated cardiomyopathy (DCM), or cardiac amyloidosis 14. Severe aortic or mitral valve stenosis 15. Pregnancy or lactation period 16. Expected survival time of less than 1 year 17. Refusal to sign the informed consent form 18. Other conditions deemed ineligible by the researchers

Primary outcome measure(s)

Postoperative Average Heart Rate by 24-Hour Ambulatory Electrocardiogram — Baseline, 1, 3, 6 and 12 months after ablation.
Average heart rate measured using 24-hour ambulatory electrocardiogram monitoring.

Trial sites (1)

Facility	City	Region	Status
Beijing Anzhen Hospital, Capital Medical University	Beijing	China	Recruiting

More Beijing Anzhen Hospital trials in China

Catheter Ablation of Haemodynamically Not-tolerated Electrical Storm in Structural Heart Disease Starting soon

Arrhythmia Cohort Study Starting soon

Safety and Efficacy of Conscious Sedation Versus General Anesthesia in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation Active, not recruiting

Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation Recruiting

Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE) Active, not recruiting

Other trials for the same condition

Pacing Characteristics of a Conventional Bipolar Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07468383 on ClinicalTrials.gov ↗ ← All trials in China